Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 4/20 | 0.33 |
| ▸ | MMP1 | P03956 | 1/20 | 0.33 |
| ▸ | MMP2 | P08253 | 1/20 | 0.33 |
| ▸ | MMP3 | P08254 | 1/20 | 0.33 |
| ▸ | MMP8 | P22894 | 1/20 | 0.33 |
| ▸ | DNM1 | Q05193 | 3/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | ALDH2 | P05091 | 1/20 | 0.31 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA9 | Q16790 | 1/20 | 0.31 |
| ▸ | THRB | P10828 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7681683 | 0.92 | DNM1 (0.42) | TSHRDNM1TDP1ALDH1A1CA12 | |
| SCHEMBL8107788 | 0.84 | DNM1 (0.35) | TSHRMMP1MMP2MMP3MMP8 | |
| SCHEMBL8114586 | 0.84 | MMP1 (0.31) | TSHRMMP1MMP2MMP3MMP8 | |
| SCHEMBL7115358 | 0.82 | FDPS (0.39) | — | |
| Hydrochloric Acid SCHEMBL7371395 | 0.80 | FDPS (0.37) | — | |
| SCHEMBL7681925 | 0.78 | MMP1 (0.33) | TSHRMMP1MMP2MMP3MMP8 | |
| Hydrochloric Acid SCHEMBL11529391 | 0.76 | DNM1 (0.35) | TSHRMMP1MMP2MMP3MMP8 | |
| SCHEMBL11195464 | 0.74 | MMP1 (0.34) | TSHRMMP1MMP2MMP3MMP8 | |
| SCHEMBL8113003 | 0.74 | DNM1 (0.35) | TSHRDNM1TDP1ALDH1A1 | |
| SCHEMBL3312355 | 0.72 | MMP1 (0.33) | TSHRMMP1MMP2MMP3MMP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012120544-A2 | PROCESS FOR N-[2-n-BUTYL-3-[4-[3-(DI-n-BUTYLAMINO) PROPOXY]ENZOYL]BENZOFURAN-5-YL]METHANESULFONAMIDE HYDROCHLORIDE | SUN PHARMACEUTICAL INDUSTRIES LTD. (IN) | 2012-09-13 | — | — | WO | claimed |
| WO-2012032545-A1 | PROCESSES FOR PREPARING DRONEDARONE AND ITS INTERMEDIATES | CADILA HEALTHCARE LIMITED (IN) | 2012-03-15 | — | — | WO | claimed |
| US-9174958-B2 | Process for the preparation of dronedarone | SANOFI (FR) | 2015-11-03 | — | — | US | disclosed |
| US-8889734-B2 | Process for the preparation of dronedarone | SANOFI (FR) | 2014-11-18 | — | — | US | disclosed |
| US-8816103-B2 | Process for the preparation of dronedarone | SANOFI (FR) | 2014-08-26 | — | — | US | disclosed |
| US-20130261321-A1 | PROCESS FOR THE PREPARATION OF DRONEDARONE | SANOFI (FR) | 2013-10-03 | — | — | US | disclosed |
| US-8501971-B2 | Process for the preparation of dronedarone | SANOFI (FR) | 2013-08-06 | — | — | US | disclosed |
| EP-2595978-A1 | NOVEL PROCESS FOR THE PREPARATION OF DRONEDARONE | SANOFI (FR) | 2013-05-29 | — | — | EP | disclosed |
| EP-2595977-A1 | PROCESS FOR PREPARING BENZOFURAN DERIVATIVES SUBSTITUTED AT POSITION 5 | SANOFI (FR) | 2013-05-29 | — | — | EP | disclosed |
| US-20130131358-A1 | Novel Process for the Preparation of Dronedarone | SANOFI (FR) | 2013-05-23 | — | — | US | disclosed |
| US-20130109868-A1 | Process for the Preparation of Dronedarone | SANOFI (FR) | 2013-05-02 | — | — | US | disclosed |
| US-4880824-A | CARDIOVASCULAR DISORDERS | ORTHO PHARMACEUTICAL CORPORATION (US) | 1989-11-14 | — | — | US | disclosed |
| US-4871745-A | LOCAL ANESTHETICS | ORTHO PHARMACEUTICAL CORPORATION (US) | 1989-10-03 | — | — | US | disclosed |
| US-4791117-A | LOCAL ANTESTHETICS, ANTISECRETORY AGENTS | ORTHO PHARMACEUTICAL CORPORATION (US) | 1988-12-13 | — | — | US | disclosed |
| EP-0261912-A2 | 2- or 3- Aryl substituted imidazo [1,2-a] pyridines | ORTHO PHARMACEUTICAL CORPORATION (US) | 1988-03-30 | — | — | EP | disclosed |
| US-4727145-A | LOCAL ANESTHETICS | ORTHO PHARMACEUTICAL CORPORATION (US) | 1988-02-23 | — | — | US | disclosed |
| EP-0235111-A1 | Indolizine derivatives, process for their preparation and compositions containing them | SANOFI S.A. (FR) | 1987-09-02 | — | — | EP | disclosed |
| US-4520026-A | ANTIARRHYTHMIA AGENTS | S. A. LABAZ N.V. (BE) | 1985-05-28 | — | — | US | disclosed |
| US-4378362-A | CARDIOVASCULAR DISORDERS | S.A. LABAZ N.V. (BE) | 1983-03-29 | — | — | US | disclosed |
| US-4220645-A | CARDIOVASCULAR DISORDERS | THEA (THERAPEUTIQUE ET APPLICATIONS) SA (FR) | 1980-09-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130131358-A1 | Novel Process for the Preparation of Dronedarone | CYP2F1, CYP3A4, CYP2D6 | TSHR 3893/4885MMP1 4070/4885MMP2 2422/4885 |
| US-20130109868-A1 | Process for the Preparation of Dronedarone | CYP2D6, CYP2B6, CYP2F1 | TSHR 4058/4885MMP1 4262/4885MMP2 2412/4885 |
| US-20130261321-A1 | PROCESS FOR THE PREPARATION OF DRONEDARONE | CYP2D6, CYP3A4, CYP4B1 | TSHR 3871/4885MMP1 4476/4885MMP2 3968/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.